"CDC is collaborating with public health and regulatory officials in several states and the U.S. Food and Drug Administration (FDA) to investigate a multistate outbreak of Listeria monocytogenes infections (listeriosis). The joint investi"...
Pharmacokinetics And Drug Metabolism
Maximal plasma cefdinir concentrations occur 2 to 4 hours postdose following capsule or suspension administration. Plasma cefdinir concentrations increase with dose, but the increases are less than dose-proportional from 300 mg (7 mg/kg) to 600 mg (14 mg/kg). Following administration of suspension to healthy adults, cefdinir bioavailability is 120% relative to capsules. Estimated bioavailability of cefdinir capsules is 21% following administration of a 300 mg capsule dose, and 16% following administration of a 600 mg capsule dose. Estimated absolute bioavailability of cefdinir suspension is 25%. Cefdinir oral suspension of 250 mg/5 mL strength was shown to be bioequivalent to the 125 mg/5 mL strength in healthy adults under fasting conditions.
Effect of Food
The Cmax and AUC of cefdinir from the capsules are reduced by 16% and 10%, respectively, when given with a high-fat meal. In adults given the 250 mg/5 mL oral suspension with a high-fat meal, the Cmax and AUC of cefdinir are reduced by 44% and 33%, respectively. The magnitude of these reductions is not likely to be clinically significant because the safety and efficacy studies of oral suspension in pediatric patients were conducted without regard to food intake. Therefore, cefdinir may be taken without regard to food.
Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 300- and 600-mg oral doses of cefdinir to adult subjects are presented in the following table:
Mean (± SD) Plasma Cefdinir Pharmacokinetic Parameter
Values Following Administration of Capsules to Adult Subjects
|Dose||Cmax (μg/mL)||tmax (hr)||AUC (μg•hr/mL)|
|300 mg||1.6 (0.55)||2.9 (0.89)||7.05 (2.17)|
|600 mg||2.87 (1.01)||3 (0.66)||11.1 (3.87)|
Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 7- and 14-mg/kg oral doses of cefdinir to pediatric subjects (age 6 months-12 years) are presented in the following table:
Mean (± SD) Plasma Cefdinir Pharmacokinetic Parameter
Values Following Administration of Suspension to Pediatric Subjects
|7 mg/kg||2.3 (0.65)||2.2 (0.6)||8.31 (2.5)|
|14 mg/kg||3.86 (0.62)||1.8 (0.4)||13.4 (2.64)|
Cefdinir does not accumulate in plasma following once- or twice-daily administration to subjects with normal renal function.
The mean volume of distribution (Vdarea) of cefdinir in adult subjects is 0.35 L/kg (± 0.29); in pediatric subjects (age 6 months-12 years), cefdinir Vdarea is 0.67 L/kg (± 0.38). Cefdinir is 60% to 70% bound to plasma proteins in both adult and pediatric subjects; binding is independent of concentration.
In adult subjects, median (range) maximal blister fluid cefdinir concentrations of 0.65 (0.33-1.1) and 1.1 (0.49-1.9) μg/mL were observed 4 to 5 hours following administration of 300- and 600mg doses, respectively. Mean (± SD) blister Cmax and AUC (0-∞) values were 48% (± 13) and 91% (± 18) of corresponding plasma values.
In adult patients undergoing elective tonsillectomy, respective median tonsil tissue cefdinir concentrations 4 hours after administration of single 300- and 600-mg doses were 0.25 (0.220.46) and 0.36 (0.22-0.80) μg/g. Mean tonsil tissue concentrations were 24% (± 8) of corresponding plasma concentrations.
In adult patients undergoing elective maxillary and ethmoid sinus surgery, respective median sinus tissue cefdinir concentrations 4 hours after administration of single 300- and 600-mg doses were < 0.12 ( < 0.12-0.46) and 0.21 ( < 0.12-2.0) μg/g. Mean sinus tissue concentrations were 16% (± 20) of corresponding plasma concentrations.
In adult patients undergoing diagnostic bronchoscopy, respective median bronchial mucosa cefdinir concentrations 4 hours after administration of single 300- and 600-mg doses were 0.78 ( < 0.06-1.33) and 1.14 ( < 0.06-1.92) μg/mL, and were 31% (± 18) of corresponding plasma concentrations. Respective median epithelial lining fluid concentrations were 0.29 ( < 0.3-4.73) and 0.49 ( < 0.3-0.59) μg/mL, and were 35% (± 83) of corresponding plasma concentrations.
Middle Ear Fluid
In 14 pediatric patients with acute bacterial otitis media, respective median middle ear fluid cefdinir concentrations 3 hours after administration of single 7- and 14-mg/kg doses were 0.21 ( < 0.09-0.94) and 0.72 (0.14-1.42) μg/mL. Mean middle ear fluid concentrations were 15% (± 15) of corresponding plasma concentrations.
Data on cefdinir penetration into human cerebrospinal fluid are not available.
Metabolism and Excretion
Cefdinir is not appreciably metabolized. Activity is primarily due to parent drug. Cefdinir is eliminated principally via renal excretion with a mean plasma elimination half-life (t½) of 1.7 (± 0.6) hours. In healthy subjects with normal renal function, renal clearance is 2.0 (± 1.0) mL/min/kg, and apparent oral clearance is 11.6 (± 6.0) and 15.5 (± 5.4) mL/min/kg following doses of 300- and 600-mg, respectively. Mean percent of dose recovered unchanged in the urine following 300- and 600-mg doses is 18.4% (± 6.4) and 11.6% (± 4.6), respectively. Cefdinir clearance is reduced in patients with renal dysfunction (see Special Populations - Patients with Renal Insufficiency).
Because renal excretion is the predominant pathway of elimination, dosage should be adjusted in patients with markedly compromised renal function or who are undergoing hemodialysis (see DOSAGE AND ADMINISTRATION).
Patients with Renal Insufficiency
Cefdinir pharmacokinetics were investigated in 21 adult subjects with varying degrees of renal function. Decreases in cefdinir elimination rate, apparent oral clearance (CL/F), and renal clearance were approximately proportional to the reduction in creatinine clearance (CLcr). As a result, plasma cefdinir concentrations were higher and persisted longer in subjects with renal impairment than in those without renal impairment. In subjects with CLcr between 30 and 60 mL/min, Cmax and t½ increased by approximately 2-fold and AUC by approximately 3-fold. In subjects with CLcr < 30 mL/min, Cmax increased by approximately 2-fold, t½ by approximately 5fold, and AUC by approximately 6-fold. Dosage adjustment is recommended in patients with markedly compromised renal function (creatinine clearance < 30 mL/min; see DOSAGE AND ADMINISTRATION).
Cefdinir pharmacokinetics were studied in 8 adult subjects undergoing hemodialysis. Dialysis (4 hours duration) removed 63% of cefdinir from the body and reduced apparent elimination t½ from 16 (± 3.5) to 3.2 (± 1.2) hours. Dosage adjustment is recommended in this patient population (see DOSAGE AND ADMINISTRATION).
Because cefdinir is predominantly renally eliminated and not appreciably metabolized, studies in patients with hepatic impairment were not conducted. It is not expected that dosage adjustment will be required in this population.
The effect of age on cefdinir pharmacokinetics after a single 300-mg dose was evaluated in 32 subjects 19 to 91 years of age. Systemic exposure to cefdinir was substantially increased in older subjects (N = 16), Cmax by 44% and AUC by 86%. This increase was due to a reduction in cefdinir clearance. The apparent volume of distribution was also reduced, thus no appreciable alterations in apparent elimination t½ were observed (elderly: 2.2 ± 0.6 hours vs young: 1.8 ± 0.4 hours). Since cefdinir clearance has been shown to be primarily related to changes in renal function rather than age, elderly patients do not require dosage adjustment unless they have markedly compromised renal function (creatinine clearance < 30 mL/min, see Patients with Renal Insufficiency, above).
Gender and Race
The results of a meta-analysis of clinical pharmacokinetics (N = 217) indicated no significant impact of either gender or race on cefdinir pharmacokinetics.
Mechanism of Action
As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, β-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir.
Mechanism of Resistance
Resistance to cefdinir is primarily through hydrolysis by some β-lactamases, alteration of penicillin-binding proteins (PBPs) and decreased permeability. Cefdinir is inactive against most strains of Enterobacter spp., Pseudomonas spp., Enterococcus spp., penicillin-resistant streptococci, and methicillin-resistant staphylococci. β-lactamase negative, ampicillin-resistant (BLNAR) H. influenzae strains are typically non-susceptible to cefdinir.
Cefdinir has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in INDICATIONS AND USAGE.
Staphylococcus aureus (methicillin-susceptible
Streptococcus pneumoniae (penicillin-susceptible strains only)
The following in vitro data are available, but their clinical significance is unknown.
Cefdinir exhibits in vitro minimum inhibitory concentrations (MICs) of 1 mcg/mL or less against ( ≥ 90%) strains of the following microorganisms; however, the safety and effectiveness of cefdinir in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.
Staphylococcus epidermidis (methicillin-susceptible
Viridans group streptococci
Susceptibility Test Methods
When available, the clinical microbiology laboratory should provide periodic reports that describe the regional/local susceptibility profile of potential nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug for treatment.
Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method1 (broth and/or agar). The MIC values should be interpreted according to criteria provided in Table 1.
Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized method.2 The procedure uses paper disks impregnated with 5 mcg cefdinir to test the susceptibility of bacteria. The disk diffusion interpretive criteria are provided in Table 1.
Table 1: Susceptibility Test Interpretive Criteria for
|Microorganismsa||Minimum Inhibitory Concentration (mcg/mL)||Zone Diameter (mm)|
|Haemophilus influenzae||≤ 1||—||—||≥ 20||—||—|
|Haemophilus parainfluenzae||≤ 1||—||—||≥ 20||—||—|
|Moraxella catarrhalis||≤ 1||2||≥ 4||≥ 20||17 - 19||≤ 16|
|Streptococcus pneumoniaeb||≤ 0.5||1||≥ 2||—||—||—|
|Streptococcus pyogenes||≤ 1||2||≥ 4||≥ 20||17 - 19||≤ 16|
|aStreptococci other than S. pneumoniae that are
susceptible to penicillin (MIC ≤ 0.12 mcg/mL), can be considered
susceptible to cefdinir.
bS. pneumoniae that are susceptible to penicillin (MIC ≤ 0.06 mcg/mL) can be considered susceptible to cefdinir. Isolates of S. pneumoniae tested against a 1-μg oxacillin disk with oxacillin zone sizes ≥ 20 mm are susceptible to penicillin and can be considered susceptible to cefdinir. Testing of cefdinir against penicillin-intermediate or penicillin-resistant isolates is not recommended. Reliable interpretive criteria for cefdinir are not available.
Susceptibility of staphylococci to cefdinir may be deduced from testing penicillin and either cefoxitin or oxacillin. Staphylococci susceptible to oxacillin (cefoxitin) can be considered susceptible to cefdinir.3
A report of “Susceptible” indicates that antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the site of infection necessary to inhibit growth of the pathogen. A report of “Intermediate” indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected.
Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individual performing the test.1,2,3 Standard cefdinir powder should provide the following range of MIC values as noted in Table 2. For the diffusion technique using a 5 mcg disk the criteria in Table 2 should be achieved.
Table 2: Acceptable Quality Control Ranges for
|QC Strain||Minimum Inhibitory Concentration (mcg/mL)||Zone Diameter (mm)|
|Escherichia coli ATCC 25922||0.12 - 0.5||24 - 28|
|Haemophilus influenzae ATCC 49766||0.12 - 0.5||24 - 31|
|Staphylococcus aureus ATCC 25923||--||25 - 32|
|Staphylococcus aureus ATCC 29213||0.12 - 0.5||--|
|Streptococcus pneumoniae ATCC 49619||0.03 - 0.25||26 - 31|
Community-Acquired Bacterial Pneumonia
In a controlled, double-blind study in adults and adolescents conducted in the US, cefdinir BID was compared with cefaclor 500 mg TID. Using strict evaluability and microbiologic/clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained:
US Community-Acquired Pneumonia Study Cefdinir vs Cefaclor
|Cefdinir BID||Cefaclor TID||Outcome|
|Clinical Cure Rates||150/187 (80%)||147/186 (79%)||Cefdinir equivalent to control|
|Eradication Rates Overall||177/195 (91%)||184/200 (92%)||Cefdinir equivalent to control|
|S. pneumoniae||31/31 (100%)||35/35 (100%)|
|H. influenzae||55/65 (85%)||60/72 (83%)|
|M. catarrhalis||10/10 (100%)||11/11 (100%)|
|H. parainfluenzae||81/89 (91%)||78/82 (95%)|
In a second controlled, investigator-blind study in adults and adolescents conducted primarily in Europe, cefdinir BID was compared with amoxicillin/clavulanate 500/125 mg TID. Using strict evaluability and clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained:
Pneumonia Study Cefdinir vs Amoxicillin/Clavulanate
|Cefdinir BID||Amoxicillin/ Clavulanate TID||Outcome|
|Clinical Cure Rates||83/104 (80%)||86/97 (89%)||Cefdinir not equivalent to control|
|Eradication Rates Overall||85/96 (89%)||84/90 (93%)||Cefdinir equivalent to control|
|S. pneumoniae||42/44 (95%)||43/44 (98%)|
|H. influenzae||26/35 (74%)||21/26 (81%)|
|M. catarrhalis||6/6 (100%)||8/8 (100%)|
|H. parainfluenzae||11/11 (100%)||12/12 (100%)|
In four controlled studies conducted in the United States, cefdinir was compared with 10 days of penicillin in adult, adolescent, and pediatric patients. Two studies (one in adults and adolescents, the other in pediatric patients) compared 10 days of cefdinir QD or BID to penicillin 250 mg or 10 mg/kg QID. Using strict evaluability and microbiologic/ clinical response criteria 5 to 10 days posttherapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained:
Pharyngitis/Tonsillitis Studies Cefdinir (10 days) vs
Penicillin (10 days)
|Study||Efficacy Parameter||Cefdinir QD||Cefdinir BID||Penicillin QID||Outcome|
|Adults/ Adolescents||Eradication of S. pyogenes||192/210 (91%)||199/217 (92%)||181/217 (83%)||Cefdinir superior to control|
|Clinical Cure Rates||199/210 (95%)||209/217 (96%)||193/217 (89%)||Cefdinir superior to control|
|Pediatric Patients||Eradication of S. pyogenes||215/228 (94%)||214/227 (94%)||159/227 (70%)||Cefdinir superior to control|
|Clinical Cure Rates||222/228 (97%)||218/227 (96%)||196/227 (86%)||Cefdinir superior to control|
Two studies (one in adults and adolescents, the other in pediatric patients) compared 5 days of cefdinir BID to 10 days of penicillin 250 mg or 10 mg/kg QID. Using strict evaluability and microbiologic/clinical response criteria 4 to 10 days posttherapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained:
Studies Cefdinir (5 days) vs Penicillin (10 days)
|Study||Efficacy Parameter||Cefdinir BID||Penicillin QID||Outcome|
|Adults/ Adolescents||Eradication of S. pyogenes||193/218 (89%)||176/214 (82%)||Cefdinir equivalent to control|
|Clinical Cure Rates||194/218 (89%)||181/214 (85%)||Cefdinir equivalent to control|
|Pediatric Patients||Eradication of S. pyogenes||176/196 (90%)||135/193 (70%)||Cefdinir superior to control|
|Clinical Cure Rates||179/196 (91%)||173/193(90%)||Cefdinir equivalent to control|
1. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard – Tenth Edition. CLSI Document M07-A10 , Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA.
2. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Twelfth Edition. CLSI Document M02-A12 , Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA.
3. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fifth Informational Supplement, CLSI Document M100-S25 , Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA.
4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
5. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-63.
6. Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatrics 1984;104:849-54.
Last reviewed on RxList: 11/30/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Omnicef Information
Omnicef - User Reviews
Omnicef User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.